Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $165.
January 18, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald analyst reaffirms a Neutral rating on Alnylam Pharmaceuticals with a steady price target of $165.
The reiteration of a Neutral rating and maintenance of the price target by Cantor Fitzgerald is not new information and is likely to have a neutral short term impact on ALNY's stock price. The analyst's view remains unchanged, suggesting no immediate catalyst for stock movement.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100